What it is
AICAR is an AMPK-activating research compound studied for metabolic signaling and endurance protocols.
Evidence boundary
No validated human dosing protocol is available. No source-backed human AICAR dosing schedule has been established.
Trial evidence
No verified human protocol found.
Preparation and measurement
No source-backed vial, BAC, or reconstitution convention verified.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 1 mg | 6 U (0.06 mL) | Daily during cycle | 7 mg/week |
| Weeks 3–4 | 2 mg | 12 U (0.12 mL) | Daily during cycle | 14 mg/week |
| Weeks 5–8 (target) | 3 mg | 18 U (0.18 mL) | Daily during cycle | 21 mg/week |
Weeks 1–2 (titration)
- Dose
- 1 mg
- Draw / measure
- 6 U (0.06 mL)
- Frequency
- Daily during cycle
- Weekly total
- 7 mg/week
Weeks 3–4
- Dose
- 2 mg
- Draw / measure
- 12 U (0.12 mL)
- Frequency
- Daily during cycle
- Weekly total
- 14 mg/week
Weeks 5–8 (target)
- Dose
- 3 mg
- Draw / measure
- 18 U (0.18 mL)
- Frequency
- Daily during cycle
- Weekly total
- 21 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
Daily titration (subcutaneous, gradual approach):
-
Weeks 1–2: 1 mg/day (1,000 mcg).
-
Weeks 3–4: 2 mg/day (2,000 mcg).
-
Weeks 5–8 (target): 3 mg/day (3,000 mcg).
-
Advanced (literature-supported only): up to 5 mg/day.
-
Cycle: 8–12 weeks active, 4-week break. Effects compound during paired endurance training.
-
Whether the compound identity is being confused with another AMPK-related research item
-
Whether the use case is preclinical rather than human
-
No source-backed human protocol is established
Practical rules
- A human dosing schedule requires a source-backed record.